48.74 USD
▲-5.86+5.56%
盘后 46.35 +0.39%
2026-08-03
市值
$6.91B
市盈率
17.60
EPS
2.77
股息率
—
52 周区间
25.28 – 59.30
成交量
2.87M
Beta
1.60
目标价
68.57
52W 低 25.2852W 高 59.30
价格走势
公司简介
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...